Introduction
============

Echinacoside (ECH, [Figure 1](#f1-dddt-9-4685){ref-type="fig"}), a polyphenolic macromolecular carbohydrate existing in *Cistanche tubulosa* (Schrenk) R. Wight and other traditional Chinese medicines,[@b1-dddt-9-4685] possesses a variety of pharmacological activities, such as antiosteoporosis,[@b1-dddt-9-4685],[@b2-dddt-9-4685] vasorelaxation,[@b3-dddt-9-4685] neuroprotection,[@b4-dddt-9-4685],[@b5-dddt-9-4685] hepatoprotection,[@b6-dddt-9-4685] and antioxidant.[@b7-dddt-9-4685] Our previous study showed that ECH can effectively stimulate bone regeneration through increasing the ratio of osteoprotegerin and receptor activator of nuclear factor-κB ligand in MC3T3-E1 cells and in osteoporosis model in rats.[@b1-dddt-9-4685],[@b2-dddt-9-4685] However, the oral bioavailability of ECH in rats is only 0.83%.[@b8-dddt-9-4685] Therefore, it is necessary to further investigate the absorption behaviors and characteristics of ECH and search for the agent(s) to promote the absorption and oral bioavailability of ECH, as well as the possible mechanism(s).

Generally, poor oral bioavailability may result from low intestinal permeability, high metabolism, extensive biliary excretion and chemical instability in gastrointestinal juice, and discontent intestinal absorption is one of the most important factors, which count for the low oral bioavailability.[@b9-dddt-9-4685] Moreover, some efflux proteins, *P*-glycoprotein (*P*-gp) that belongs to ATP-binding cassette transporters superfamily,[@b10-dddt-9-4685] and multidrug resistance protein (MRP) that induced expression in diseases, such as cancer, which results in worsened prognosis as the malignant tissues,[@b11-dddt-9-4685] are abundant in the human intestines, and play a significant role in drug absorption, transport, and bioavailability.[@b12-dddt-9-4685] In addition, some plant essential oils could act as absorption promoters to improve intestinal absorption of active ingredients from traditional Chinese medicines.[@b13-dddt-9-4685]--[@b15-dddt-9-4685] Borneol,[@b15-dddt-9-4685]--[@b17-dddt-9-4685] pennyroyal,[@b15-dddt-9-4685] and clove oil[@b15-dddt-9-4685],[@b18-dddt-9-4685] are all natural plant essential oils and have been reported as absorption promoters used in many articles.

In this study, we evaluated two efflux protein inhibitors (verapamil, *P*-gp inhibitor;[@b19-dddt-9-4685] probenecid, MRP inhibitor[@b20-dddt-9-4685]), and three absorption-enhancing agents (borneol, pennyroyal, and clove oil) by everted gut sac model in vitro and single-pass intestinal perfusion model in situ, and evaluated the influences of verapamil and clove oil on ECH oral bioavailability. Finally, we found out that verapamil and clove oil increased intestinal absorption and oral bioavailability of ECH and probed the potential mechanism(s) preliminary.

Materials and methods
=====================

Materials and reagents
----------------------

ECH, borneol, verapamil, and probenecid were bought from Chinese National Institute for the control of pharmaceutical and biological products (Beijing, People's Republic of China). Pennyroyal and clove oil were purchased from Nanjing Chemical Reagent Co., Ltd (Nanjing, People's Republic of China). Methanol of chromatographic grade was obtained from Hanbon Science and Technology (Huai'an, People's Republic of China). All of the other chemicals and solvents were of analytical reagent grade.

The perfusion solution was Krebs--Ringer (K--R) buffer solution, which contained 7.8 g NaCl, 0.35 g KCl, 1.37 g NaHCO~3~, 0.02 g MgCl~2~, 0.32 g NaH~2~PO~4~, and 1.48 g glucose in 1,000 mL deionized water.

Animals
-------

Male Sprague Dawley (SD) rats (200--250 g) were obtained from the Animal Center of Nantong University (Nantong, People's Republic of China), and housed in cages under controlled humidity at room temperature (28°C±2°C). Twelve-hour light/dark cycle was maintained, and standard diet and water were available ad libitum. Animal experiments were conducted after due clearance from Animals Ethics Committee of the University.

Preparation of everted gut sac model in vitro
---------------------------------------------

Everted gut sac methods were performed as described previously.[@b13-dddt-9-4685] Briefly, 16--24 hours fasted SD rats were anesthetized with 20% urethane (ip 1.3 g/kg). The abdomen was opened by a midline incision (2--3 cm), and then duodenums, jejunums, ileums, and colons (\~10 cm each) were rapidly removed from the anesthetized rat and placed quickly in beakers with K--R buffer solution on ice. The animals were sacrificed by cervical dislocation before recovering from anesthesia. All intestinal segments were immediately flushed with ice-cold K--R buffer solution to remove the intestinal contents and the underlying mesenterium. Each intestinal segment was tied at one end, everted with a smooth glass rod, and blotted dry to remove mucus. The everted sacs were ligated with silk thread to a hollow glass tube at the other end for sampling. The sacs were filled with 2 mL of K--R buffer solution and then incubated in different donor solutions (37°C, the K--R buffer solution with different ECH concentrations), which were aerated with 5% CO~2~ and 95% O~2~. About 0.5 mL of samples were taken out from the internal medium completely at different time intervals (15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes), and also equivalent fresh K--R buffers were added to the sacs.

Preparation of single-pass intestinal perfusion model in situ
-------------------------------------------------------------

Single-pass intestinal perfusion methods in situ were performed according to the previous report.[@b14-dddt-9-4685] SD rats were anesthetized with 20% urethane (ip 1.3 g/kg) and placed under an infrared lamp to maintain normal body temperature. The abdominal cavity was opened, and the desired intestinal segments (about 10 cm) were pulled out carefully to maintain an intact blood supply. The intestinal segments were cannulated on two ends with glass tubes and rinsed with 37°C normal saline solution until the outlet solution was visually clear. Subsequently, K--R solution containing ECH was perfused through the loop at a flow rate of 0.2 mL/min for 30 minutes to get steady-state condition. Samples were periodically collected with a weighed tube at intervals of 15 minutes and lasted for 90 minutes. After experiment, the inlet and outlet tubes were weighed and animals were sacrificed by cervical dislocation.

Study of stability and nonspecific binding of ECH
-------------------------------------------------

Preliminary studies were necessary to ensure that the loss of drug from the perfusion was due to absorption, but not other causes (eg, degradation or nonspecific binging to intestinal wall and tubes).[@b21-dddt-9-4685] The stability of ECH was tested by incubating ECH in K--R buffer and intestinal at 37°C for 2 hours. Nonspecific binding of ECH was detected by incubating ECH solution with the intestinal walls and rubber tubes.

Absorption study of ECH in different intestinal segments
--------------------------------------------------------

Everted gut sac model in vitro and single-pass intestinal perfusion model in situ were both used to test whether the intestinal absorption of ECH exhibit site dependence. The ECH solution at the same concentration (0.09 mg/mL) was perfused through the duodenum, jejunum, ileum, and colon to investigate the appropriate segment of ECH absorption.

Absorption study of ECH in different concentrations
---------------------------------------------------

In order to determine the influence of different ECH concentrations on its absorptive transport and intestinal permeability, solutions containing three concentrations of ECH (0.03 mg/mL, 0.09 mg/mL, 0.27 mg/mL) were administrated into the jejunal segments in in vitro and in situ studies, respectively, as described earlier.

Effect of efflux protein inhibitors absorption promoters on intestinal absorption behavior of ECH
-------------------------------------------------------------------------------------------------

The influence of *P*-gp and MRP on the intestinal absorption behaviors of ECH was studied by in vitro and in situ methods. The solution containing 0.2 mg/mL verapamil (*P*-gp inhibitor) and 0.09 mg/mL ECH and 0.2 mg/mL probenecid (MRP inhibitor) and 0.09 mg/mL ECH were administrated into jejunal segments, respectively as described earlier.

The intestinal absorption properties of ECH with or without absorption promoters were determined utilizing both everted gut sac model in vitro and single-pass intestinal perfusion model in situ. Borneol (0.1 mg/mL), pennyroyal (0.1 mL/mL), and clove oil (0.1 mL/mL), together with ECH (0.09 mg/mL), were perfused through the rat jejunum, respectively as described earlier.

Calculation of absorption parameters in vitro and in situ
---------------------------------------------------------

Permeation flux (*F*, µg/s), apparent permeability coefficient (*P*~app~, cm/s), intestinal effective permeability coefficient (*P*~eff~, cm/s) of drugs were calculated by the following equations[@b22-dddt-9-4685],[@b23-dddt-9-4685]: $$F = dQ/dt$$ $$Ka = (1 - C_{\text{out}}Q_{\text{out}}/C_{\text{in}}Q_{\text{in}}) \times Q/V$$ $$P_{\text{app}} = (dQ/dt) \times (1/AC_{0})$$ $$P_{\text{eff}} = - Q \times \text{ln}(C_{\text{out}}Q_{\text{out}}/C_{\text{in}}Q_{\text{in}})/2\pi rl$$where (*dQ*/*dt*) is the flux of ECH from the mucosal-to-serosal side of the mucosa; *A* (cm^2^) is the surface of the membrane and *C*~0~ (mg/mL) is the initial concentration of ECH in the donor compartment; *Q* (mL/min) is the volume flow rate of the intestine; *C*~in~ (mg/mL) and *C*~out~ (mg/mL) are the inlet and outlet concentration of drug in perfusion buffer in perfusion buffer, respectively; and the density of perfusion buffer was 1.0 g/mL both at inlet and outlet; *Q*~in~ (mL) and *Q*~out~ (mL) are the volume of perfusion buffer volume at inlet and outlet, respectively; *V* (cm^3^) is the volumes of perfusion segment; *r* is the jejunum segment luminal radius and *l* is the mean length of perfused jejunum segment.

Pharmacokinetic study
---------------------

Eighteen SD rats were randomly selected and divided into three groups (n=6) for oral administration as follows: group I, ECH (120 mg/kg); group II (ECH + V), ECH (120 mg/kg) + verapamil (0.2 mg/mL); group III (ECH + C), ECH (120 mg/kg) + clove oil (0.1 mL/mL). After overnight fasting, rats were orally administered with ECH and its combinations. Blood samples (0.5 mL) were taken from the eye ground veins at different time intervals of 0 minute, 5 minutes, 15 minutes, 30 minutes, 60 minutes, 120 minutes, 180 minutes, 240 minutes, 360 minutes, 600 minutes, and 960 minutes, then centrifuged at 4,000 rpm for 15 minutes and separated the plasma and were stored at −20°C until further analysis by high performance liquid chromatography (HPLC) method as reported.[@b24-dddt-9-4685] The bioavailability of three groups was evaluated by DAS 2.1.1 software (Shanghai, People's Republic of China).

Statistical analyses
--------------------

The results were all presented as mean ± standard deviation. Data were analyzed by one-way analysis of variance and LSD *t*-test using SPSS (Version 15.0, SPSS Inc., Chicago, IL, USA). A probability level of *P*\<0.05 was considered to be significantly different.

Results
=======

Stability and nonspecific binding of ECH
----------------------------------------

ECH was found to be stable both in K--R buffer solution and intestinal perfusate in 2-hour incubation. The results showed that no ECH was absorbed by intestinal wall and tubes in everted gut sac and single-pass intestinal perfusion experiment ([Figure 2](#f2-dddt-9-4685){ref-type="fig"}). The incubation results suggested that any loss of drug from the perfusion should be attributed to intestinal absorption.

Site dependence of ECH absorption
---------------------------------

The absorption parameters of ECH in four different intestinal segments were evaluated by everted gut sac method in vitro as shown in [Figure 3](#f3-dddt-9-4685){ref-type="fig"}, there was no significant statistical difference in *F* and *P*~app~ among duodenum, jejunum, and ileum (*P*\>0.05). Both *F* and *P*~app~ of these three segments were higher than colon (*P*\<0.01). The in vitro results demonstrated that ECH was mostly absorbed in the small intestine rather than the colon, though the absorption of ECH had no specificity among the above three small intestine segments.

Data gained in the single-pass intestinal perfusion in situ data also illustrated that the small intestine was the appropriate segment of absorption for ECH, and [Figure 4](#f4-dddt-9-4685){ref-type="fig"} showed that the absorption rate constant (*Ka*) and *P*~eff~ of ECH from duodenum, jejunum, and ileum were significantly higher, compared to colon (*P*\<0.01). Additionally, no significant statistical differences were observed among these three segments (*P*\>0.05), and the result were consistent with in vitro results, which suggested that ECH had higher absorption in small intestine segments compared to colon segment.

Concentration dependence of ECH absorption
------------------------------------------

Jejunum was selected to study concentration dependence of ECH absorption in in vitro model. As shown in [Figure 5A](#f5-dddt-9-4685){ref-type="fig"}, compared to 0.03 mg/mL group, *F* and *P*~app~ were lower than 0.09 mg/mL and 0.27 mg/mL (*P*\>0.05), but there was no statistical difference between the above concentration groups.

[Figure 5B](#f5-dddt-9-4685){ref-type="fig"} depicted the absorption parameters *Ka* and *P*~eff~ evaluated by single-pass intestinal perfusion model in situ. The results showed *Ka* and *P*~eff~ in 0.09 mg/mL and 0.27 mg/mL group were significantly higher than 0.03 mg/mL group (*P*\>0.05). The above results indicated that ECH might cross the intestinal barrier by carrier-mediated uptake/efflux pathways in jejunum.

Effect of efflux protein inhibitors and absorption promoters on ECH absorption
------------------------------------------------------------------------------

Some efflux proteins, such as *P*-gp and MRP, had an important influence on drug accumulation and transport in intestine.[@b25-dddt-9-4685] Therefore, it was necessary to evaluate the influence of verapamil (*P*-gp inhibitor) and probenecid (MRP inhibitor) on the absorption parameters of ECH. [Figure 6A](#f6-dddt-9-4685){ref-type="fig"} showed the changes of ECH absorption parameters *F* and *P*~app~ between the groups with or without verapamil and probenecid in in vitro everted gut sac system. Compared to control group, the *F* and *P*~app~ in verapamil group were significantly increased (*P*\<0.05), and which implicated that ECH might be the substrate of *P*-gp. Besides, as shown in [Figure 6B](#f6-dddt-9-4685){ref-type="fig"}, the *Ka* and *P*~eff~ in verapamil group in in situ model were much higher (*P*\<0.01) in comparison with control group, and which was consistent with the in vitro results, and similarly suggesting that ECH was the substrate of *P*-gp.

Some essential plant oils could improve the intestinal absorption of saponins with low intestinal permeability.[@b13-dddt-9-4685] In this study, the influence of borneol, pennyroyal, and clove oil on the ECH intestinal absorption properties were investigated by using in vitro and in situ experiment and the potential absorption enhancer was studied. The absorption parameters were presented in [Figure 7](#f7-dddt-9-4685){ref-type="fig"} ([Figure 7A](#f7-dddt-9-4685){ref-type="fig"}, in vitro; [Figure 7B](#f7-dddt-9-4685){ref-type="fig"}, in situ). These results showed that the intestinal absorption of ECH was significantly increased by clove oil compared to control group (*P*\<0.05). However, neither borneol nor pennyroyal had significant absorption enhancing effect.

Pharmacokinetic study
---------------------

Mean plasma concentration--time profiles were illustrated in [Figure 8](#f8-dddt-9-4685){ref-type="fig"} and the pharmacokinetic parameters *C*~max~, *T*~max~, MRT~0−~*~t~*, MRT~0−∞~, AUC~0−24~, AUC~0−∞~, and CLz/*F* of ECH alone and its combination with verapamil and clove oil in rat plasma were summarized in [Table 1](#t1-dddt-9-4685){ref-type="table"}, respectively. The bioavailability of ECH after oral administration in combination with verapamil and clove oil has been significantly increased by 1.37-fold (*P*\<0.05) and 2.36-fold (*P*\<0.001), when compared to ECH alone. Furthermore, the *C*~max~ value of ECH + V and ECH + C were about 1.4-fold and 2.58-fold higher than ECH. From these results, the pharmacokinetics was all fitted two-compartment model after a single dose of ECH and with its combination. The mechanism(s) of promoting the bioavailability of ECH by verapamil and clove oil will be further investigated in the future study.

Discussion
==========

Various in vitro, in situ, and in vivo models have been developed to evaluate drug absorption in intestine, such as Caco-2 cell monolayer model, everted gut sac model, single-pass intestinal perfusion model, and each model has its merits and demerits. Therefore, simultaneous utilization of two independent models as a cross-validation of experimental system would produce reliable values when studying intestinal absorption.[@b26-dddt-9-4685] In this present study, everted gut sac model in vitro and single-pass intestinal perfusion in situ were employed to study the intestinal absorption characteristics of ECH and to obtain reliable results. The consistent conclusions were obtained from the in vitro and in situ models in this research; however, the statistical significances of parameters among some paired groups were different, which was caused by different prediction accuracy of the two models, and this was in accordance with the previous report.[@b26-dddt-9-4685]

Orally administrated drug may cross the intestinal barrier by single pathway or combination of several pathways, including passive transcellular diffusion, passive paracellular diffusion, and carrier-mediated uptake or efflux transport.[@b27-dddt-9-4685] In the present report, there was no concentration dependence of ECH absorption, and a saturable absorption appeared when the concentration was higher than 0.09 mg/mL. The concentration independence coupled with the saturable absorption suggested that ECH was transported via carrier-mediated uptake/efflux pathways in jejunum. Moreover, verapamil could significantly improve the absorption of ECH, and which indicated that ECH was the substrate of *P*-gp. In order to identify the other specific protein involved in the carrier-mediated process, experiments about cells transfected with the gene coding need to be conducted in future.[@b21-dddt-9-4685]

Site dependence of ECH absorption was observed based on the in vitro and in situ experiments. The lowest absorption was observed in colon, which was consistent with many previous reports.[@b13-dddt-9-4685],[@b14-dddt-9-4685] This might be due to a decreased total surface area of membrane and increased tightness of the epithelium in the colonic region.[@b28-dddt-9-4685],[@b29-dddt-9-4685] Moreover, it was suitable to prepare sustained release preparation to extend the remained time of ECH in small intestine and to improve the absorption.

According to biopharmaceutics classification system, drugs with *P*~eff~ \<0.03×10^−4^ cm/s in the small intestine of rat on in situ perfusion model are regarded as poor absorption, whereas *P*~eff~\>0.2×10^−4^ cm/s are complete absorption.[@b30-dddt-9-4685] The highest permeability of ECH in the whole intestine was 3.23×10^−6^ cm/s, and which indicated that intestinal absorption of ECH was poor, and this result was in accordance with the result from the study conducted on a Caco-2 cell monolayer model.[@b31-dddt-9-4685] In addition, low intestinal permeability of ECH might be a count for its poor oral bioavailability.

Until now, some plant essential oils have been adopted to improve the intestinal absorption of active ingredients in traditional Chinese medicine.[@b13-dddt-9-4685]--[@b15-dddt-9-4685] In the present research, clove oil, extracted from *Eugenia caryophyllata* and consisted of eugenol, acetyleugenol, and other terpenes with various carbon numbers, was demonstrated to have a promotion on the intestinal absorption of ECH across the jejunal barrier.[@b18-dddt-9-4685] Our results agreed with some previous studies that clove oil could improve oral absorption of polysaccharides and increase some drugs' transdermal penetration.[@b15-dddt-9-4685],[@b18-dddt-9-4685] The potential mechanism(s) of clove oil for improving absorption may alter lipid phase of the intestinal mucous membrane, accelerate fluidity of polar head group regions of cell membranes, and loosen the intercellular tight junction in intestinal tract.[@b13-dddt-9-4685],[@b14-dddt-9-4685] However, the exact mechanism(s) was not fully understood and deserved further investigation.

In the animal model study, the relative bioavailability of ECH alone and ECH with combinations were evaluated, and the results show that the ECH oral bioavailability was elevated by verapamil and clove oil by nearly 1.37-fold and 2.36-fold when it compared to ECH alone. It is possible that the absorption and bioavailability of ECH could be further elevated when the ECH, verapamil, and clove oil were combined.

Conclusion
==========

Both in vitro and in situ intestinal absorption experiments consistently demonstrated that ECH absorption was poor and site dependent. In addition, ECH had higher absorption in small intestine than in colon and without segment specificity among small intestine. ECH was the substrate of *P*-gp, and jejunal absorption could be improved by using clove oil. The absorption mechanism(s) in jejunum may be carrier-mediated uptake/efflux pathways. Moreover, the improvement of intestinal permeability and absorption augment by clove oil and inhibiting *P*-gp-mediated efflux by verapamil could result in the oral bioavailability enhancement of ECH. Importantly, the influence on ECH intestinal absorption and oral bioavailability by its combination, with both verapamil and clove oil warrants further study, as well as the development of promising agent(s) for ECH bioavailability augment.
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![Chemical structure of ECH.\
**Abbreviation:** ECH, echinacoside.](dddt-9-4685Fig1){#f1-dddt-9-4685}

![Stability and nonspecific binding of ECH.\
**Notes:** (**A**) ECH remaining percent after 2 h in K--R buffer solution and homogenates of rat intestinal segments. (**B**) Binding of ECH to tubes and different sections of intestine after 2-h incubation. Results were shown as mean ± SD (n=3 in each group).\
**Abbreviations:** ECH, echinacoside; h, hours; K--R, Krebs--Ringer; SD, standard deviation.](dddt-9-4685Fig2){#f2-dddt-9-4685}

![Site dependence of ECH absorption evaluated by in vitro everted gut sac model.\
**Notes:** (**A**) Permeation flux of ECH in four different intestinal segments: duodenum, jejunum, ileum, and colon. (**B**) Apparent permeability coefficient of ECH in four intestinal segments such as duodenum, jejunum, ileum, and colon. Results were shown as mean ± SD (n=6 in each group). \*\**P*\<0.01 versus colon group.\
**Abbreviations:** ECH, echinacoside; SD, standard deviation; *P*~app~, apparent permeability coefficient; *F*, permeation flux.](dddt-9-4685Fig3){#f3-dddt-9-4685}

![Site dependence of ECH absorption evaluated by in situ single-pass intestinal perfusion model.\
**Notes:** (**A**) Absorption rate constant, *Ka*. (**B**) Effective permeability coefficient, *P*~eff~. Results were shown as mean ± SD (n=6 in each group). \*\**P*\<0.01 versus colon group.\
**Abbreviations:** ECH, echinacoside; SD, standard deviation.](dddt-9-4685Fig4){#f4-dddt-9-4685}

![Absorption parameters of ECH in different concentrations.\
**Notes:** (**A**) *F* and *P*~app~ came from in vitro everted gut sac experiment. (**B**) *Ka* and *P*~eff~ came from in situ single-pass intestinal perfusion experiment. Results were shown as mean ± SD (n=6 in each group). \**P*\<0.05, \*\**P*\<0.01 versus the low concentration group. ^\#^*P*\<0.05, ^\#\#^*P*\<0.01 versus the middle concentration group.\
**Abbreviations:** ECH, echinacoside; *P*~app~, apparent permeability coefficient; *P*~eff~, effective permeability coefficient; SD, standard deviation; *Ka*, absorption rate constant; *F*, permeation flux.](dddt-9-4685Fig5){#f5-dddt-9-4685}

![Absorption parameters of ECH in the absence or presence of two different efflux protein inhibitors.\
**Notes:** (**A**) *F* and *P*~app~ came from in vitro everted gut sac experiment. (**B**) *Ka* and *P*~eff~ came from in situ single-pass intestinal perfusion experiment. Results were shown as mean ± SD (n=6 in each group). ^\#^*P*\<0.05, ^\#\#^*P*\<0.01 versus the control group.\
**Abbreviations:** ECH, echinacoside; *P*~app~, apparent permeability coefficient; *P*~eff~, effective permeability coefficient; SD, standard deviation; *Ka*, absorption rate constant; *F*, permeation flux.](dddt-9-4685Fig6){#f6-dddt-9-4685}

![Absorption parameters of ECH in the absence or presence of three different absorption promoters.\
**Notes:** (**A**) *F* and *P*~app~ came from in vitro everted gut sac experiment. (**B**) *Ka* and *P*~eff~ came from in situ single-pass intestinal perfusion experiment. Results were shown as mean ± SD (n=6 in each group). ^\#^*P*\<0.05, ^\#\#^*P*\<0.01 versus the control group.\
**Abbreviations:** ECH, echinacoside; *P*~app~, apparent permeability coefficient; *P*~eff~, effective permeability coefficient; SD, standard deviation; *Ka*, absorption rate constant; *F*, permeation flux.](dddt-9-4685Fig7){#f7-dddt-9-4685}

![Plasma concentration profiles in rats after oral administrations of ECH and ECH with combinations.\
**Notes:** Results were shown as mean ± SD (n=6 in each group). \**P*\<0.05; \*\**P*\<0.01 versus ECH group.\
**Abbreviations:** ECH, echinacoside; SD, standard deviation; V, verapamil; C, clove oil.](dddt-9-4685Fig8){#f8-dddt-9-4685}

###### 

The main pharmacokinetic parameters of echinacoside with absorption promoters clove oil and efflux protein inhibitors verapamil in rats plasma (mean ± SD, n=6)

  Parameters              ECH               ECH + verapamil                                                ECH + clove oil
  ----------------------- ----------------- -------------------------------------------------------------- -----------------------------------------------------------------
  AUC~0--24~ (µg/L·min)   370.744±48.204    536.555±49.462[\*\*](#tfn2-dddt-9-4685){ref-type="table-fn"}   899.901±74.100[\*\*](#tfn2-dddt-9-4685){ref-type="table-fn"}
  AUC~0--∞~ (µg/L·min)    483.815±143.336   661.363±55.121[\*](#tfn1-dddt-9-4685){ref-type="table-fn"}     1,141.271±286.613[\*\*](#tfn2-dddt-9-4685){ref-type="table-fn"}
  MRT~0--~*~t~* (min)     328.397±33.452    322.564±17.958                                                 300.796±44.939
  MRT~0--∞~ (min)         672.547±301.549   619.213±137.42                                                 573.291±262.976
  *T* ~max~ (min)         100.000±30.984    87.500±30.619                                                  100.000±15.492
  CLz/*F* (min)           262.753±60.553    182.559±16.105[\*](#tfn1-dddt-9-4685){ref-type="table-fn"}     110.007±23.403[\*\*](#tfn2-dddt-9-4685){ref-type="table-fn"}
  *C*~max~ (µg/L)         1.118±0.115       1.570±0.226[\*\*](#tfn2-dddt-9-4685){ref-type="table-fn"}      2.890±0.483[\*\*](#tfn2-dddt-9-4685){ref-type="table-fn"}

**Notes:**

*P*\<0.05,

*P*\<0.01 versus the ECH group.

**Abbreviations:** SD, standard deviation; ECH, echinacoside; min, minute; C~max~, peak concentration; T~max~, peak time; MRT, mean retention time; AUC~0--24~, area under concentration-time curve from 0 to 24 h; AUC~0--∞~, area under concentration-time curve from 0 to ∞; CLz/F, clearance rate calibrated by bioavailability.
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